Benitec Biopharma (BNTC) Total Current Liabilities (2019 - 2025)

Benitec Biopharma (BNTC) has 7 years of Total Current Liabilities data on file, last reported at $2.8 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities fell 9.32% year-over-year to $2.8 million; the trailing twelve-month figure through Dec 2025 stood at $2.8 million (down 9.32% YoY), and the FY2025 full-year result was $1.8 million, down 63.4% from the prior year.
• Total Current Liabilities climbed to $2.8 million in Q4 2025, from $2.0 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $7.0 million in Q1 2025 to a low of $1.4 million in Q2 2021.
• A 5-year average of $3.2 million and a median of $2.9 million in 2022 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 218.36% in 2021 and plunged 63.4% in 2025, its largest moves.
• Tracing BNTC's Total Current Liabilities over 5 years: stood at $2.5 million in 2021, then gained by 0.36% to $2.5 million in 2022, then jumped by 130.86% to $5.7 million in 2023, then slumped by 46.24% to $3.1 million in 2024, then retreated by 9.32% to $2.8 million in 2025.
• Business Quant data shows BNTC's Total Current Liabilities at $2.8 million in Q4 2025, $2.0 million in Q3 2025, and $1.8 million in Q2 2025.